Patent awarded for synthetic compounds with medical applications

December 01, 2014

MANHATTAN, Kansas -- A patent has been issued for a series of synthetic compounds developed at Kansas State University that have applications for treating cancer and other diseases that affect cell communication.

The compounds, called quinolines, can restart communication between adjacent cells in the body if those communication channels have become closed from a disease.

U.S. Patent 8,809,368, "Compounds Affecting Gap Junction Activity," was recently awarded to the Kansas State University Research Foundation, a nonprofit corporation responsible for managing technology transfer activities at the university. The patent is for research conducted by Duy Hua, university distinguished professor of chemistry; Thu "Annelise" Nguyen, associate professor of toxicology; and Dolores Takemoto, professor emeritus of biochemistry.

In 2007, Hua developed several new quinolines -- colorless, pungent, oily liquids that are naturally found in coal tar.

Based on computational modeling with the quinolines, Hua believed the compounds could affect gap junction activity in cells. Gap junctions are "doorways" or channels between adjacent cells that allow small molecules, ions and the body's electrical signals to move from one cell to a neighboring cell.

Hua turned the quinolines over to Nguyen and Takemoto to study their effectiveness in real cells. The researchers looked at whether the quinolines could restore gap junction activity, and thus communication, in cells clusters that no longer had gap junction activity.

Researchers found that the quinolines developed by Hua reopened the closed channels in the cells.

"By reopening these channels, we can once again have cells functioning normally," Nguyen said. "The cells are able to regulate themselves once again with biological markers that tell cells when to die. This function is necessary for the body to function normally."

The quinolines' ability to restore lost gap junction activity may make the synthetic compounds a new resource in the fight against cancer, Nguyen said.

"In cancer cells, gap junction activity is low compared to normal cells because cancer cells have a low expression of the protein that makes up the gap junction channels," Nguyen said. "The protein is either not able to make gap junctions or the gap junctions are made closed. Here we have compounds that can restore that gap junction activity to normal."

The Kansas State University developed quinolines are currently the only gap junction enhancer in existence.
The patent is currently licensed to Sigma-Aldrich, an American life science and high technology company.

Kansas State University has been awarded eight U.S. patents in 2014.

Kansas State University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to